GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer (Q39356890)

11 September 2017

GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer (English)

1 reference

11 September 2017

Baigalimaa Luvsandagva

1

1 reference

11 September 2017

Kazuto Nakamura

2

1 reference

11 September 2017

Yoshikazu Kitahara

3

1 reference

11 September 2017

Hiroshi Aoki

4

1 reference

11 September 2017

Tomomi Murata

5

1 reference

11 September 2017

Sadatomo Ikeda

6

1 reference

11 September 2017

Takashi Minegishi

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

25 April 2012

1 reference

11 September 2017

1 reference

11 September 2017

126

1 reference

11 September 2017

132-139

1 reference

11 September 2017

1

1 reference

The glucose-regulated proteins: stress induction and clinical applications

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Protein degradation in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

De-regulation of GRP stress protein expression in human breast cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Stress induction of GRP78/BiP and its role in cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

ER stress, hypoxia tolerance and tumor progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Glucose regulated proteins in cancer progression, drug resistance and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Cancer control in women. Update 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Over-expression of heat shock proteins in carcinogenic endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Systematic review of systemic therapy for advanced or recurrent endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Taxol stabilizes microtubules in mouse fibroblast cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Identification of highly conserved regulatory domains and protein-binding sites in the promoters of the rat and human genes encoding the stress-inducible 78-kilodalton glucose-regulated protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Functional polymorphisms of HSPA5: possible association with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Estrogen receptor alpha interaction with estrogen response element half-sites from the rat prolactin gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Endoplasmic reticulum stress is activated in endometrial adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.025

10.1016/J.YGYNO.2012.04.025

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference